Andrea Pilotto, MD, University of Brescia, Brescia, Italy, describes his recent study looking at the ability of plasma markers to detect Alzheimer’s disease (AD) in a real-world clinical setting. A total of 65 patients with AD (based on clinical and cerebrospinal fluid assessments) underwent testing for plasma p-tau, neurofilament light (NfL), GFAP, and Aβ42/Aβ40. Results were compared to healthy controls and patients with other neurodegenerative diseases to assess the use of each biomarker in the differential diagnosis of AD. It was shown that p-tau181 and p-tau231 were the most able to distinguish AD cases from controls and other disorders. Dr Pilotto explains the value of both markers for diagnostic screening and the added certainty that can be achieved with additional plasma Aβ testing. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
